CoChat

Drug Resistance in Toxoplasma gondii

Open access
Montazeri, Mahbobeh, Mehrzadi, Saeed, Sharif, Mehdi, Sarvi, Shahabeddin, Tanzifi, Asal, Aghayan, Sargis A., Daryani, Ahmad · 2018 · Frontiers in Microbiology
Cited by 217

The DOI matches its Crossref record.

Abstract

Toxoplasma gondii (T. gondii) is a global protozoan parasite infecting up to one-third of the world population. The most widely used drugs for treatment of toxoplasmosis are pyrimethamine (PYR) and sulfadiazine (SDZ); however, several failure cases have been recorded as well; suggesting the existence of drug resistant strains. In this systematic review, the data was collected from six English data bases (PubMed, Science Direct, Scopus, Google Scholar, ISI Web of Science and EBSCO) to evaluate drug resistance in T. gondii including in vitro and in vivo studies. Results of the present review were 34 research papers evaluated 37 drugs and compounds and more than 100 resistant strains of T. gondii during 1977- February 2017. In 12 surveys, T. gondii mutants were identified as a good model to study mechanisms of resistance and drug target in parasites. Interestingly, analogous amino acid substitutions in the Toxoplasma enzyme identified to confer PYR resistance. Moreover, resistance to clindamycin, spiramycin and azithromycin is encoded in the rRNA genes of T. gondii. However, T. gondii SDZ resistance mechanism has not been proved yet. As the only worrying trend is a very slight recent increase in the SDZ resistance, most of the studies were carried out using SDZ. Six resistance strains to SDZ were found in clinical cases between 2013 and 2017. Among them the Brazilian T. gondii isolates, of TgCTBr11, Ck3 and Pg1 were identified in human toxoplasmosis, as well as in livestock intended for human consumption. In conclusion, recent experimental studies in clinical cases have clearly shown that drug resistance in Toxoplasma is ongoing. Thus, establish a more effective therapeutic scheme in the treatment of toxoplasmosis is critically needed. The emergence of T. gondii strains resistant to cur¬rent drugs, reviewed here, repre¬sents a concern not only for treatment failure but also for increased clinical severity in immunocompromised patients. To improve the therapeutic outcome in patients, development of a greater understanding of exact mechanisms of drug resistance in T. gondii is needed. Additionally, monitoring the presence of resistant parasites, in food products, would thus seem a prudent public health program.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2018.02587

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 80

  1. Alday, 2017, Drugs in development for toxoplasmosis: advances, challenges, and current status, Drug Des. Dev. Ther., 11, 273, 10.2147/DDDT.S60973 · DOI · Paper page
  2. Alves, 2005, Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil, Parasite, 12, 171, 10.1051/parasite/2005122171 · doi:10.1051/parasite/2005122171
  3. Aspinall, 2002, The molecular basis of sulfonamide resistance in Toxoplasma gondii and implications for the clinical management of toxoplasmosis, J. Infect. Dis., 185, 1637, 10.1086/340577 · DOI
  4. Berens, 1998, Selection and characterization of Toxoplasma gondii mutants resistant to artemisinin, J. Infect. Dis., 177, 1128, 10.1086/517411 · doi:10.1086/517411
  5. Bossi, 1998, Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994, Rev. Med. Interne, 19, 313, 10.1016/S0248-8663(98)80100-8 · doi:10.1016/s0248-8663(98)80100-8
  6. Capper, 2015, Antimalarial 4 (1H)-pyridones bind to the Qi site of cytochrome bc1, Proc. Natl. Acad. Sci. U. S. A., 112, 755, 10.1073/pnas.1416611112 · DOI
  7. Chirgwin, 2002, Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 study, Clin. Infect. Dis., 34, 1243, 10.1086/339551 · doi:10.1086/339551
  8. Crofts, 2004, The cytochrome bc1 complex: function in the context of structure, Annu. Rev. Physiol, 66, 689, 10.1146/annurev.physiol.66.032102.150251 · DOI · Paper page
  9. Cui, 2015, Antimalarial drug resistance: literature review and activities and findings of the ICEMR network, Am. J. Trop. Med. Hyg., 93, 57, 10.4269/ajtmh.15-0007 · DOI · Paper page
  10. Daryani, 2018, The potential use of melatonin to treat protozoan parasitic infections: a review, Biomed. Pharmacother., 97, 948, 10.1016/j.biopha.2017.11.007 · doi:10.1016/j.biopha.2017.11.007
  11. Doggett, 2012, Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis, Proc. Natl. Acad. Sci. U. S. A., 109, 15936, 10.1073/pnas.1208069109 · DOI · Paper page
  12. Doliwa, Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters, Parasite, 20, 19, 10.1051/parasite/2013020 · DOI
  13. Doliwa, Induction of sulfadiazine resistance in vitro in Toxoplasma gondii, Exp. Parasitol, 133, 131, 10.1016/j.exppara.2012.11.019 · DOI
  14. Doliwa, Identification of differentially expressed proteins in sulfadiazine resistant and sensitive strains of Toxoplasma gondii using difference-gel electrophoresis (DIGE), Int. J. Parasitol. Drugs Drug Resist., 3, 35, 10.1016/j.ijpddr.2012.12.002 · doi:10.1016/j.ijpddr.2012.12.002
  15. Donald, 1993, Stable molecular transformation of Toxoplasma gondii: a selectable dihydrofolate reductase-thymidylate synthase marker based on drug-resistance mutations in malaria, Proc. Natl. Acad. Sci. U. S. A, 90, 11703, 10.1073/pnas.90.24.11703 · doi:10.1073/pnas.90.24.11703
  16. Fox, 1999, Stable transformation of Toxoplasma gondii based on a pyrimethamine resistant trifunctional dihydrofolate reductase-cytosine deaminase-thymidylate synthase gene that confers sensitivity to 5-fluorocytosine, Mol. Biochem. Parasitol, 98, 93, 10.1016/S0166-6851(98)00154-6 · doi:10.1016/s0166-6851(98)00154-6
  17. Gajurel, 2016, Failure of primary atovaquone prophylaxis for prevention of toxoplasmosis in hematopoietic cell transplant recipients, Transpl. Infect. Dis., 18, 446, 10.1111/tid.12532 · doi:10.1111/tid.12532
  18. Garrison, 2009, Disruption of a mitochondrial MutS DNA repair enzyme homologue confers drug resistance in the parasite Toxoplasma gondii, Mol. Microbiol, 72, 425, 10.1111/j.1365-2958.2009.06655.x · doi:10.1111/j.1365-2958.2009.06655.x
  19. Glasner, 1992, An unusually high prevalence of ocular toxoplasmosis in southern Brazil, Am. J. Ophthalmol., 114, 136, 10.1016/S0002-9394(14)73976-5 · DOI · Paper page
  20. Hegewald, 2013, Identification of dihydroorotate dehydrogenase as a relevant drug target for 1-Hydroxyquinolones in Toxoplasma gondii, Mol. Biochem. Parasitol, 190, 6, 10.1016/j.molbiopara.2013.05.008 · doi:10.1016/j.molbiopara.2013.05.008
  21. Howe, 1995, Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease, J. Infect. Dis, 172, 1561, 10.1093/infdis/172.6.1561 · DOI · Paper page
  22. Jacobson, 1996, Pyrimethamine pharmacokinetics in human immunodeficiency virus-positive patients seropositive for Toxoplasma gondii, Antimicrob. Agents Chemother., 40, 1360, 10.1128/AAC.40.6.1360 · doi:10.1128/aac.40.6.1360
  23. Kessl, 2006, Molecular basis of Toxoplasma gondii atovaquone resistance modeled in Saccharomyces cerevisiae, Mol. Biochem. Parasitol, 146, 255, 10.1016/j.molbiopara.2005.12.002 · DOI
  24. Kovacs, 1992, Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS, Lancet, 340, 637, 10.1016/0140-6736(92)92172-C · DOI
  25. Kropf, 2012, The adaptive potential of a survival artist: characterization of the in vitro interactions of Toxoplasma gondii tachyzoites with di-cationic compounds in human fibroblast cell cultures, Parasitology, 139, 208, 10.1017/S0031182011001776 · doi:10.1017/s0031182011001776
  26. Lavine, 2012, Analysis of monensin sensitivity in Toxoplasma gondii reveals autophagy as a mechanism for drug induced death, PLoS ONE, 7, e42107, 10.1371/journal.pone.0042107 · DOI
  27. Lawres, 2016, Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquone, J. Exp. Med., 27, 1307, 10.1084/jem.20151519 · DOI
  28. Lindsay, 1995, Ultrastructural effects of diclazuril against Toxoplasma gondii and investigation of a diclazuril-resistant mutant, J. Parasitol, 81, 459, 10.2307/3283832 · doi:10.2307/3283832
  29. Luft, 1992, Toxoplasmic encephalitis in AIDS, Clin. Infect. Dis, 15, 211, 10.1093/clinids/15.2.211 · DOI · Paper page
  30. Ma, 2007, Mutations in α-tubulin confer dinitroaniline resistance at a cost to microtubule function, Mol. Biol. Cell, 18, 4711, 10.1091/mbc.e07-04-0379 · DOI
  31. Ma, 2008, Secondary mutations correct fitness defects in Toxoplasma gondii with dinitroaniline resistance mutations, Genetics, 180, 845, 10.1534/genetics.108.092494 · doi:10.1534/genetics.108.092494
  32. McFadden, 2001, Resistance as a tool in the study of old and new drug targets in Toxoplasma, Drug Resist. Updates, 4, 79, 10.1054/drup.2001.0184 · DOI
  33. McFadden, 1997, Use of Toxoplasma gondii expressing -galactosidase for colorimetric assessment of drug activity in vitro, Antimicrob. Agents Chemother., 41, 1849, 10.1128/AAC.41.9.1849 · doi:10.1128/aac.41.9.1849
  34. McFadden, 2000, Characterization of cytochrome b from Toxoplasma gondii and Q o domain mutations as a mechanism of atovaquone-resistance, Mol. Biochem. Parasitol, 108, 1, 10.1016/S0166-6851(00)00184-5 · DOI · Paper page
  35. McLeod, 2006, Outcome of treatment for congenital toxoplasmosis, 1981–2004: the national collaborative Chicago-based, congenital toxoplasmosis study, Clin. Infect. Dis, 42, 1383, 10.1086/501360 · DOI · Paper page
  36. Meneceur, 2008, In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone, Antimicrob. Agents.Chemother., 52, 1269, 10.1128/AAC.01203-07 · DOI
  37. Moncada, 2012, Toxoplasmosis in the fetus and newborn: an update on prevalence, diagnosis and treatment, Expert Rev. Anti Infect. Ther, 10, 815, 10.1586/eri.12.58 · DOI · Paper page
  38. Montazeri, 2015, Effect of propranolol alone and in combination with pyrimethamine on acute murine toxoplasmosis, Jundishapur J.Microbiol, 8, e22572, 10.5812/jjm.22572 · doi:10.5812/jjm.22572
  39. Montazeri, 2018, Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review, Parasitol. Res, 117, 3045, 10.1007/s00436-018-6027-z · DOI
  40. Montazeri, Survey on synergism effect of ketotifen in combination with pyrimethamine in treatment of acute murine toxoplasmosis, Trop. Med. Int, 45, 39, 10.1186/s41182-017-0079-0 · doi:10.1186/s41182-017-0079-0
  41. Montazeri, A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006–2016), Front Microbiol., 8, 25, 10.3389/fmicb.2017.00025 · DOI · Paper page
  42. Montoya, 2004, Toxoplasmosis, Lancet, 363, 1965, 10.1016/S0140-6736(04)16412-X · DOI · Paper page
  43. Morrissette, 2004, Dinitroanilines bind α-tubulin to disrupt microtubules, Mol. Biol. Cell, 15, 1960, 10.1091/mbc.e03-07-0530 · DOI
  44. Nagamune, 2007, Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis, Antimicrob. Agents Chemother., 51, 3816, 10.1128/AAC.00582-07 · DOI
  45. Nair, 2011, Apicoplast isoprenoid precursor synthesis and the molecular basis of fosmidomycin resistance in Toxoplasma gondii, J. Exp. Med, 208, 1547, 10.1084/jem.20110039 · DOI
  46. Oliveira, 2016, Pathogenicity and phenotypic sulfadiazine resistance of Toxoplasma gondii isolates obtained from livestock in northeastern Brazil, Mem Inst Oswaldo Cruz, 111, 391, 10.1590/0074-02760150459 · doi:10.1590/0074-02760150459
  47. Ouellette, 2001, Biochemical and molecular mechanisms of drug resistance in parasites, Trop. Med. Int. Health, 6, 874, 10.1046/j.1365-3156.2001.00777.x · DOI
  48. Oz, 2014, Novel synergistic protective efficacy of atovaquone and diclazuril on fetal-maternal toxoplasmosis, Int. J. Clin. Med, 5, 921, 10.4236/ijcm.2014.515124 · DOI
  49. Pappas, 2009, Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis, Int. J. Parasitol., 39, 1385, 10.1016/j.ijpara.2009.04.003 · DOI · Paper page
  50. Pfefferkorn, Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin, Antimicrob. Agents Chemother., 38, 31, 10.1128/AAC.38.1.31 · doi:10.1128/aac.38.1.31
  51. Pfefferkorn, Toxoplasma gondii: characterization of a mutant resistant to 6-thioxanthine, Exp Parasitol, 79, 374, 10.1006/expr.1994.1099 · doi:10.1006/expr.1994.1099
  52. Pfefferkorn, Toxoplasma gondii: characterization of a mutant resistant to sulfonamides, Exp Parasitol, 74, 261, 10.1016/0014-4894(92)90149-5 · DOI
  53. Pfefferkorn, 1993, Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate, J. Parasitol, 79, 559, 10.2307/3283383 · doi:10.2307/3283383
  54. Pfefferkorn, 1988, Toxoplasma gondii: in vivo and in vitro studies of a mutant resistant to arprinocid-N-oxide, Exp. Parasitol, 65, 282, 10.1016/0014-4894(88)90133-6 · doi:10.1016/0014-4894(88)90133-6
  55. Pfefferkorn, 1983, Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance, Exp. Parasitol., 55, 207, 10.1016/0014-4894(83)90015-2 · doi:10.1016/0014-4894(83)90015-2
  56. Pfefferkorn, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob. Agents Chemother., 36, 1091, 10.1128/AAC.36.5.1091 · doi:10.1128/aac.36.5.1091
  57. Pfefferkorn, 1977, Toxoplasma gondii: characterization of a mutant resistant to 5-fluorodeoxyuridine, Exp. Parasitol, 42, 44, 10.1016/0014-4894(77)90060-1 · doi:10.1016/0014-4894(77)90060-1
  58. Pfefferkorn, 1978, The biochemical basis for resistance to adenine arabinoside in a mutant of Toxoplasma gondii, J. Parasitol, 64, 486, 10.2307/3279789 · DOI
  59. Pfefferkorn, 1980, Toxoplasma gondii: genetic recombination between drug resistant mutants, Exp. Parasitol., 50, 305, 10.1016/0014-4894(80)90034-X · doi:10.1016/0014-4894(80)90034-x
  60. Porter, 1992, Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome, N. Engl. J. Med, 327, 1643, 10.1056/NEJM199212033272306 · DOI · Paper page
  61. Rajapakse, 2013, Antibiotics for human toxoplasmosis: a systematic review of randomized trials, Pathog. Glob. Health, 107, 162, 10.1179/2047773213Y.0000000094 · DOI
  62. Reynolds, 2001, In Vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase, Antimicrob. Agents Chemother., 45, 1271, 10.1128/AAC.45.4.1271-1277.2001 · doi:10.1128/aac.45.4.1271-1277.2001
  63. Reynolds, 1998, A biochemical and genetic model for parasite resistance to antifolates Toxoplasma gondii provides insights into pyrimethamine and cycloguanil resistance in Plasmodium falciparum, J. Biol. Chem, 273, 3461, 10.1074/jbc.273.6.3461 · DOI
  64. Ricketts, 1993, Toxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro, Antimicrob. Agents Chemother., 37, 2358, 10.1128/AAC.37.11.2358 · doi:10.1128/aac.37.11.2358
  65. Sander, 1971, Development of sulphonamide resistance in Toxoplasma gondii, APMIS, 79, 531
  66. Schultz, 2014, A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice, J. Parasitol, 100, 516, 10.1645/13-451.1 · doi:10.1645/13-451.1
  67. Sepúlveda-Arias, 2014, Toxoplasmosis as a travel risk, Travel Med. Infect. Dis., 12, 592, 10.1016/j.tmaid.2014.05.007 · doi:10.1016/j.tmaid.2014.05.007
  68. Shwab, 2014, Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR- RFLP genotyping, Parasitology, 141, 453, 10.1017/S0031182013001844 · DOI · Paper page
  69. Silva, 2017, Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in minas gerais, Brazil, PloS ONE, 12, e0170689, 10.1371/journal.pone.0170689 · DOI
  70. Sims, 2009, Drug resistance in Toxoplasma gondii, 1121, 10.1007/978-1-60327-595-8_31 · DOI
  71. Sugi, 2010, Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step, Eukaryotic Cell, 9, 667, 10.1128/EC.00351-09 · doi:10.1128/ec.00351-09
  72. Sugi, 2015, A single mutation in the gatekeeper residue in TgMAPKL-1 restores the inhibitory effect of a bumped kinase inhibitor on the cell cycle, Int. J. Parasitol. Drugs Drug Resist., 5, 1, 10.1016/j.ijpddr.2014.12.001 · DOI
  73. Sugi, 2013, Identification of mutations in TgMAPK1 of Toxoplasma gondii conferring resistance to 1NM-PP1, Int. J. Parasitol. Drugs Drug Resist, 3, 93, 10.1016/j.ijpddr.2013.04.001 · doi:10.1016/j.ijpddr.2013.04.001
  74. Tenter, 2000, Toxoplasma gondii: from animals to humans, Int. J. Parasitol., 30, 1217, 10.1016/S0020-7519(00)00124-7 · DOI · Paper page
  75. Tomavo, 1995, Interconnection between organellar functions, development and drug resistance in the protozoan parasite, Toxoplasma gondii, Int. J. Parasitol., 25, 1293, 10.1016/0020-7519(95)00066-B · DOI
  76. Vaillant, 2005, Foodborne infections in France, Foodborne Pathog. Dis, 2, 221, 10.1089/fpd.2005.2.221 · DOI · Paper page
  77. Van Voorhis, 2017, Extended-spectrum antiprotozoal bumped kinase inhibitors: a review, Exp. Parasitol., 180, 71, 10.1016/j.exppara.2017.01.001 · DOI
  78. Villena, 1998, Pyrimethamine-sulfadoxine treatment of congenital toxoplasmosis: follow-up of 78 cases between 1980 and 1997, Scand. J. Infect. Dis, 30, 295, 10.1080/00365549850160963 · DOI
  79. Wang, 2017, Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis, Front. Microbiol., 8, 389, 10.3389/fmicb.2017.00389 · DOI · Paper page
  80. Winter, 2008, Antimalarial quinolones: synthesis, potency, and mechanistic studies, Exp. Parasitol., 118, 487, 10.1016/j.exppara.2007.10.016 · doi:10.1016/j.exppara.2007.10.016

Cited by

See all 217

Metadata

Authors
Montazeri, M., Mehrzadi, S., Sharif, M., Sarvi, S., Tanzifi, A., Aghayan, S. A., & Daryani, A.
Venue
Frontiers in Microbiology
Published
2018-10-29
Volume
9
Pages
2587-2587
ISSN
1664-302X (ISSN-L)
OpenAlex
W2898821708
Cited by
217
References
0
FWCI
12.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug Resistance in Toxoplasma gondii. https://app.cochat.ai/papers/10.3389/fmicb.2018.02587
The paper
Montazeri, M., Mehrzadi, S., Sharif, M., Sarvi, S., Tanzifi, A., Aghayan, S. A., & Daryani, A. (2018). Drug Resistance in Toxoplasma gondii. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2018.02587

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.